Metastasis Clinical Trial
— PRO-CARBOOfficial title:
Multicentre, Open-label Phase 2 Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway
Verified date | April 2021 |
Source | Centre Francois Baclesse |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The investigators propose a phase II study to evaluate the efficacy of carboplatin monotherapy in the tumor subgroup of metastatic castration-resistant prostatic carcinomas with somatic abnormality in the Homologous Recombination (HR) pathway. This study may also better characterize the molecular abnormalities of tumors required for the carboplatin response
Status | Terminated |
Enrollment | 16 |
Est. completion date | April 27, 2021 |
Est. primary completion date | April 27, 2021 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients > 18 years old - Patients with adenocarcinoma or poorly differentiated prostate carcinoma, histologically confirmed (small-cell histology or high-grade neuroendocrine histology excluded) - Tumor presenting a somatic pathogenic variant likely to alter the homologous recombination pathway previously detected on a tumor biopsy or on circulating tumor DNA, or germinal mutation among the list of genes defined in the study - Castration-resistant tumor defined by progression despite well-conducted androgen deprivation treatment: testosterone =50ng /dL agonist / antagonist of luteinizing hormone-releasing hormone (LHRH) or surgical castration. The patient must agree to continue concomitant LHRH-mediated (agonist or antagonist) therapy throughout the duration of the study regimen for patients with no history of surgical castration. - Patients must have performed at least one line of chemotherapy by taxane in case of castration resistance: - Patients who have received docetaxel treatment in a hormone-sensitive situation must have received at least treatment with cabazitaxel in case of castration resistance - Patients who have not received chemotherapy in a hormone-sensitive situation must have received docetaxel AND cabazitaxel or have a contraindication to discontinue treatment. - Patients must have been treated with at least 2nd generation hormone therapy (eg, abiraterone acetate or enzalutamide) - Patients may have been treated with a poly (ADP-ribose) polymerase inhibitor (PARP) - Performance Status <2 - Metastatic disease progressive Exclusion Criteria: - Absence of previous treatment with taxane in situation of sensitivity or resistance to castration. - Absence of previous treatment with cabazitaxel in case of resistance to castration (except contraindication explaining the non-administration of treatment) - No treatment with 2nd generation hormone therapy (eg abiraterone acetate or enzalutamide) unless contraindicated to explain non-administration of treatment - Previous treatment with platinum - Symptomatic and untreated central nervous system (CNS) metastases. Patients with asymptomatic and pre-treated CNS metastases are included if they are clinically stable (not requiring corticosteroid therapy for 28 days) and must have a brain MRI evaluation at screening and during follow-up. |
Country | Name | City | State |
---|---|---|---|
France | Centre François Baclesse | Caen | |
France | Centre Oscar Lambret | Lille | |
France | Chu Rouen | Rouen | |
France | Institut Gustave ROUSSy IGR | Villejuif |
Lead Sponsor | Collaborator |
---|---|
Centre Francois Baclesse | GIRCI (French Interregional Group of Clinical Research and Innovation), Ligue Contre le Cancer (French association Against Cancer) |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Efficacy of carboplatin on metastatic prostatic carcinoma resistant to castration Efficacy of carboplatin: The best radiological tumoral response rate | Tumoral response rate (TR) defined according to the recommendations of the PCWG3 criteria : Objective radiological response | Up to 27 weeks (9 cycles) | |
Primary | Efficacy of carboplatin: biological response rate defined by value of PSA | Biological response rate (TR) defined according to the recommendations of the PCWG3 criteria : Decrease of PSA = 50%, | Up to 27 weeks (9 cycles) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Terminated |
NCT03257722 -
Pembrolizumab + Idelalisib for Lung Cancer Study
|
Phase 1/Phase 2 | |
Recruiting |
NCT01201096 -
Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE)
|
N/A | |
Completed |
NCT01206530 -
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01199822 -
Study of the Safety and Pharmacokinetics of IMC-3G3 in Japanese Patients With Solid Tumors
|
Phase 1 | |
Completed |
NCT00313859 -
Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC
|
Phase 2 | |
Completed |
NCT00377936 -
EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas
|
Phase 2 | |
Recruiting |
NCT05095207 -
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04392479 -
TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.
|
Phase 3 | |
Recruiting |
NCT04808466 -
Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy
|
Phase 2 | |
Not yet recruiting |
NCT04845490 -
Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy
|
Phase 2 | |
Recruiting |
NCT05061082 -
Genomic Evolution of Metastasis in Gastric Cancer
|
||
Not yet recruiting |
NCT06055764 -
Role of FDG PET/CT in Patients With Metastasis of Unknown Origin
|
||
Terminated |
NCT02796729 -
CEST- Glucose Enhanced MRI for Metastatic Brain Tumours
|
Phase 2 | |
Withdrawn |
NCT01157039 -
A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin
|
Phase 2 | |
Terminated |
NCT01000948 -
A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer
|
Phase 2 | |
Terminated |
NCT01613482 -
TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention
|
Phase 3 | |
Withdrawn |
NCT00244348 -
Hepatic Artery Infusion With Oxaliplatin
|
Phase 1/Phase 2 | |
Recruiting |
NCT04416165 -
Comparison of FDG and FAPI in Patients With Various Types of Cancer
|
N/A | |
Recruiting |
NCT04617457 -
Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas
|
Phase 2 |